tiprankstipranks
United Therapeutics (UTHR)
NASDAQ:UTHR

United Therapeutics Stock Analysis & Ratings

UTHR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$158.38 - $243.30
Previous Close$238.29
Volume378.34K
Average Volume (3M)502.88K
Market CapN/A
Enterprise ValueN/A
P/E Ratio16.5
Beta0.37
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

UTHR FAQ

What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $158.38 and its highest was $243.30 in the past 12 months.
    What is United Therapeutics’s market cap?
    Currently, no data Available
    What is United Therapeutics’s price target?
    The average price target for United Therapeutics is $254.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $300.00 ,the lowest forecast is $238.00. The average price target represents 7.88% Increase from the current price of $235.64.
      What do analysts say about United Therapeutics?
      United Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
        When is United Therapeutics’s upcoming earnings report date?
        United Therapeutics’s upcoming earnings report date is Aug 03, 2022 which is in 33 days.
          How were United Therapeutics’s earnings last quarter?
          United Therapeutics released its earnings results on May 04, 2022. The company reported $5.03 earnings per share for the quarter, beating the consensus estimate of $3.646 by $1.384.
            Is United Therapeutics overvalued?
            According to Wall Street analysts United Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does United Therapeutics pay dividends?
              United Therapeutics does not currently pay dividends.
              What is United Therapeutics’s EPS estimate?
              United Therapeutics’s EPS estimate is $4.42.
                How many shares outstanding does United Therapeutics have?
                United Therapeutics has 45,299,510 shares outstanding.
                  What happened to United Therapeutics’s price movement after its last earnings report?
                  United Therapeutics reported an EPS of $5.03 in its last earnings report, beating expectations of $3.646. Following the earnings report the stock price went up 3.718%.
                    Which hedge fund is a major shareholder of United Therapeutics?
                    Among the largest hedge funds holding United Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds United Therapeutics’s shares valued at 68M.

                      ---

                      United Therapeutics Stock Analysis

                      The United Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      United Therapeutics

                      United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Gilead Sciences
                      Baxter International
                      Reata Pharmaceuticals
                      Bellerophon
                      Eiger Biopharmaceuticals

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis